On February 16, 2024, lifileucel (Amtagvi), a tumor-derived autologous T-cell immunotherapy, was granted accelerated approval for adults with unresectable or metastatic melanoma previously treated with a PD-1–blocking antibody, and if BRAF V600 mutation–positive, a BRAF inhibitor with or without a MEK inhibitor.
Of Interest
Adjuvant Nivolumab in Stage IIB/C Melanoma
On October 13, 2023, nivolumab was approved for adjuvant treatment of completely resected stage IIB/C melanoma in patients aged 12 years and older.
She is awarded the Sjöberg Prize for laying the foundations of a cancer vaccine
Catherine J. Wu, of the Dana-Farber Cancer Institute in Boston, USA, is a pioneer in research that may result in the development of personalised vaccines to treat cancer.
Managing Immune-Related Toxicities Key to Immunotherapy for Skin Cancer
Incidence of melanoma and keratinocyte (nonmelanoma) skin cancers, such as squamous cell and basal cell carcinomas (SCC and BCC, respectively), continues to increase, but mortality rates are stable or declining because of an explosion of treatment options, including numerous immunotherapy regimens, according to an oral presentation at the 2024 Oncology Nurse Advisor Summit.